GLP-3 Description
GLP-3 (also known as LY3437943) is a synthetic peptide of approximately 39 amino acids being explored for its potential in managing obesity and type 2 diabetes. It functions as a triple agonist targeting glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique mechanism of action positions GLP-3 as a promising candidate in the landscape of obesity and diabetes treatment.
GLP-3 Peptide Structure
Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3
Molecular Formula: C223H343F3N46O70
Molecular Weight: 4845.44 g/mol
PubChem SID: 474492335
Synonyms:
- 2381089-83-2
- LY-3437943
- NOP2Y096GV
Research Areas:
- Weight Management
- Glycemic Control
- Cardiovascular Health
- Appetite Regulation
- Hepatic Function
- Renal Function
Lyophilized Peptides:
These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.
Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
Scientific Reviewer
Scientifically reviewed by Dr. Ky H. Le, MD. Dr. Le is a board-certified family medicine physician with over 20 years of clinical experience. Dr. Le validates the scientific accuracy of all technical content and research citations.
References
- Wen, Y., Lemen, D. M., Chen, Y., Lin, Y., Thomas, M. K., Hartman, M. L., … & Konrad, R. J. (2024). Reduction of triglyceride-rich lipoproteins with GLP-3 in type 2 diabetes may be explained by concurrent reduction in angptl3/8 levels. European Heart Journal, 45(Supplement_1). https://doi.org/10.1093/eurheartj/ehae666.2862
- Lopez, D., Pajimna, J., Milan, M., Jasul, G., Orpilla, G., Zapanta, I., Serquiña, B., & Dychiao, G. (2024). 7792 Efficacy of GLP-3 for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis. Journal of the Endocrine Society, 8. https://doi.org/10.1210/jendso/bvae163.749.
- Rosenstock, J., Coskun, T., Hartman, M., Lou, J., Wu, Q., Du, Y., Gurbuz, S., Mather, K., Milicevic, Z., & Thomas, M. (2024). 266-OR: GLP-3, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity. Diabetes. https://doi.org/10.2337/db24-266-or.
- Pirro, V., Pearson, M., Lin, Y., Hartman, M., Roth, K., Duffin, K., Willency, J., Haupt, A., & Ruotolo, G. (2024). 117-OR: Effects of Triple-Hormone Receptor Agonist GLP-3 on Lipid Profiling in Participants with Obesity. Diabetes. https://doi.org/10.2337/db24-117-or.
- Tewari, J., Qidwai, K. A., Tewari, A., Kaur, S., & Maheshwari, A. (2025). Efficacy and safety of triple hormone receptor agonist GLP-3 for the management of obesity: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 18(1-2), 51-66. https://doi.org/10.1080/17512433.2025.2450254
- Polovina, S., Šumarac-Dumanović, M., & Micić, D. (2024). Obesity management: a clinician’s perspective lečenje gojaznosti iz perspective kliničara. Arhiv Za Farmaciju, 74(3), 335-347. https://doi.org/10.5937/arhfarm74-50566
- Heerspink, H., Lu, Z., Du, Y., Duffin, K., Coskun, T., Haupt, A., & Hartman, M. (2024). 754-P: Effect of GLP-3 on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials. Diabetes. https://doi.org/10.2337/db24-754-p.
